Market Place
Sourcing Support
Biocytogen Announces Adcendo ApS Exercises Antibody Option
16 Dec 2024 //
BUSINESSWIRE
IDEAYA Announces IDE034 Nomination for B7H3/PTK7 ADC
11 Nov 2024 //
PR NEWSWIRE
Biocytogen Announces IDEAYA’s Nomination of IDE034 Bispecific ADC
11 Nov 2024 //
BUSINESSWIRE
IDEAYA Announces ADC Program Agreement With Biocytogen
31 Jul 2024 //
PR NEWSWIRE
SOTIO And Biocytogen Partner On Multi-Target Antibodies For ADC Pipeline
16 Jul 2024 //
BUSINESSWIRE
Sotio taps Biocytogen to create bispecific ADCs in $326M deal
16 Jul 2024 //
FIERCE BIOTECH
Biocytogen’s RenLite common light chain mouse platform receives US patent
24 Jun 2024 //
PHARMABIZ
India`s GVSAP collaborates with China-based Biocytogen to accelerate biopharma
17 May 2024 //
FIERCE PHARMA
Biocytogen collaborates with BioCopy for TCR-mimic Antibodies evaluation.
06 May 2024 //
BUSINESSWIRE
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific ADC
25 Mar 2024 //
BUSINESSWIRE
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
20 Feb 2024 //
BUSINESSWIRE
Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
19 Feb 2024 //
BUSINESSWIRE
Biocytogen Launches RenBiologics
23 Jan 2024 //
BUSINESSWIRE
Biocytogen Enters into Bispecific ADC Agreement with Radiance
08 Jan 2024 //
BUSINESSWIRE
Biocytogen & CtM Achieve Milestone Progress in Developing a TCR-mimic Antibody
27 Dec 2023 //
BUSINESSWIRE
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Bio
19 Dec 2023 //
BUSINESSWIRE
Biocytogen Enters into Antibody Agreement with Ona Therapeutics
18 Dec 2023 //
BUSINESSWIRE
Biocytogen Announces 16 Poster Presentations and Booth Exhibition at SITC 2023
24 Oct 2023 //
BUSINESSWIRE
Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003
17 Oct 2023 //
BUSINESSWIRE
Biocytogen Officially Launches RenMice® Series
15 Sep 2023 //
BUSINESSWIRE
Biocytogen Officially Launches RenMice® Series
14 Sep 2023 //
BUSINESSWIRE
Biocytogen Enters into Antibody Evaluation, Option and Agreement with Myricx
07 Sep 2023 //
BUSINESSWIRE
Biocytogen Establishes Two Business Divisions To Distinguish Preclinical Models
30 Aug 2023 //
BUSINESSWIRE
Biocytogen Opens New Facility in Massachusetts
23 Aug 2023 //
CONTRACT PHARMA
Biocytogen’s Project Integrum Achieves Milestone Progress
17 Aug 2023 //
BUSINESSWIRE
Biocytogen Announces Grand Opening of Waltham, MA Facility
16 Aug 2023 //
BUSINESSWIRE
Pheon Therapeutics enters into license agreement with Biocytogen Pharmaceuticals
05 Jul 2023 //
PR NEWSWIRE
Biocytogen Pharmaceuticals Enters Into License Agreement With Pheon Therapeutics
05 Jul 2023 //
BUSINESSWIRE
Biocytogen Opens San Francisco Office to Accelerate Globalization
31 May 2023 //
BUSINESSWIRE
Biocytogen Announces RenLite™ Licensing Agreement with Janssen
08 Mar 2023 //
BUSINESSWIRE
Biocytogen Announces RenLite® Licensing Agreement with Janssen
08 Mar 2023 //
BUSINESSWIRE
Janssen Licenses Biocytogen`s RenLite Platform
08 Mar 2023 //
CONTRACT PHARMA
Chipscreen bags Chinese rights to Biocytogen`s Keytruda killer
27 Feb 2023 //
FIERCE BIOTECH
Biocytogen Launches “Nano 100 Project” for Nanobody Therapeutics
21 Feb 2023 //
BUSINESSWIRE
Biocytogen Launches “Nano 100 Project” to Develop Nanobody Therapeutics
20 Feb 2023 //
BUSINESSWIRE
Biocytogen Launches RenNano Mouse, a Fully Human Heavy Chain Antibody Platform
05 Jan 2023 //
BUSINESSWIRE
Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform
29 Dec 2022 //
BUSINESSWIRE
FDA approves Biocytogen’s IND application for solid tumour therapy trial
19 Dec 2022 //
CLINICALTRIALSARENA
FDA approves Biocytogen’s IND application for solid tumour therapy trial
19 Dec 2022 //
CLINICALTRIALSARENA
Biocytogen and ADC to evaluate antibodies for three cancer targets
29 Nov 2022 //
PHARMACEUTICAL-TECHNOLOGY
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
28 Nov 2022 //
BUSINESSWIRE
Biocytogen to Present Progress of Preclinical and Clinical Assets at BIO-EUROPE
17 Oct 2022 //
BUSINESSWIRE
Eucure Biopharma Licenses OX40 Antibody (YH002) and Multiple Active Ingredients
17 Oct 2022 //
BUSINESSWIRE
Biocytogen to Present at BioJapan2022
27 Sep 2022 //
BUSINESSWIRE
China promotes development of new cell therapeutic drugs
16 Sep 2022 //
BIOSPECTRUMASIA
Biocytogen Collaborates with FineImmune to Develop TCR-Mimic Cell Therapy
14 Sep 2022 //
BUSINESSWIRE
Biocytogen Lists on the Main Board of HKEX
01 Sep 2022 //
BUSINESSWIRE
Biocytogen and Tracon get FDA IND clearance for Phase I/II sarcoma trial
30 Aug 2022 //
CLINICALTRIALSARENA
US FDA Approval of IND for CTLA-4 Antibody YH001
29 Aug 2022 //
BUSINESSWIRE
Biocytogen Expands Partnership with Merck KGaA, Darmstadt, Germany
25 Aug 2022 //
BUSINESSWIRE
Beijing CRO expands agreement with Merck; Early-stage venture firm closes fund
25 Aug 2022 //
ENDPTS
Biocytogen Expands Partnership with Merck
24 Aug 2022 //
BUSINESSWIRE
Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development
21 Jul 2022 //
BUSINESSWIRE
Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development
21 Jul 2022 //
PRESS RELEASE
Biocytogen and LiberoThera Achieve Milestone Progress in Human GPCR Ab Drugs
20 Jul 2022 //
BUSINESSWIRE
Biocytogen/Eucure to Present Data from YH003 and YH001 Trials at 2022 ASCO
23 May 2022 //
ASIAONE
Biocytogen Signs RenMab/RenLite Licensing Agreement with BeiGene
25 Apr 2022 //
PRNEWSWIRE
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
25 Apr 2022 //
PRNEWSWIRE
Biocytogen Enters Agreement With CtM Bio
18 Apr 2022 //
PRNEWSWIRE
China`s Biocytogen expands global footprint with opening of innovation centre
29 Mar 2022 //
BIOSPECTRUMASIA
